#China #Shanghai #Delonix Bioworks #MenB Vaccine #DX-104

Delonix Bioworks Initiates Phase 1 Clinical Trial of DX-104

Delonix Bioworks, a cutting-edge biotechnology firm focused on genetically engineered bacterial vaccines, has announced a significant milestone: the initiation of the Phase 1 clinical trial of its innovative MenB vaccine candidate, DX-104, in China. Following the progress of a similar trial in Australia, this development underscores Delonix's commitment to tackling the pressing public health challenges posed by invasive meningococcal disease (IMD).

The Phase 1 trial, designed as a randomized, double-blind, placebo-controlled study, is set to assess both the safety and immunogenicity of DX-104 in healthy participants aged between 2 and 59 years. This approach not only aims to generate vital clinical data but also to ensure that diverse global populations are represented in the trial, reinforcing the broad applicability and benefit of the vaccine in various demographic settings.

Importance of Addressing Invasive Meningococcal Disease

Invasive meningococcal disease has emerged as a severe global health issue, with serogroup B (MenB) recognized as a leading cause, accounting for nearly 50% of IMD cases worldwide. The rising prevalence of MenB presents a critical challenge, and existing vaccines have notable limitations, especially in terms of strain coverage and global accessibility. Currently, there are no MenB vaccines authorized in China, emphasizing a significant public health void.

According to market data from Frost & Sullivan, the estimated market potential for MenB vaccines in China could reach an impressive RMB 4.7 billion by 2035. Such statistics underline the urgent need for effective solutions in this area.

Harnessing the OMV Plus® Technology

DX-104 represents a next-generation solution utilizing Delonix's proprietary OMV Plus® technology. By employing genetically engineered outer membrane vesicles (OMVs), the vaccine aims to provide precise antigen presentation, which is expected to enhance both immunogenicity and tolerability—a vital aspect when developing vaccines for the global population.

Dr. Qiubin Lin, the Founder and CEO of Delonix Bioworks, stated, "The concurrent execution of Phase 1 trials in Australia and China enables us to gather rich clinical data from a diverse patient base. This facilitates the robust validation of our OMV Plus® platform while underscoring our mission to advance global health solutions. With MenB posing significant health risks worldwide, our goal with DX-104 is to deliver a superior vaccine that is accessible and offers broader protection."

A Broader Vision Beyond MenB

Delonix Bioworks is not only focused on DX-104; the company is dedicated to advancing a pipeline of first-in-class and best-in-class programs targeting other unmet medical needs, including vaccines for conditions like pertussis, gonorrhea, and K. pneumoniae.

This latest trial initiation marks an exciting chapter in global health efforts against meningococcal disease. By combining innovative technology with a commitment to broad accessibility, Delonix Bioworks is poised to make a significant impact on public health, particularly in regions where vaccine access has previously been lacking.

For ongoing updates about Delonix Bioworks and its pioneering initiatives, interested parties are encouraged to visit Delonix Bioworks for more information.